Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930694 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02930694 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 32 participants.
The verdict
NCT02930694, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The primary purpose of the study is to investigate the plasma pharmacokinetics and bioavailability (BA) of a single dose of a solid dose formulation with 2 different strengths of JNJ-54175446 (50 milligram \[mg\] and 100 mg capsules) relative to the suspension of JNJ-54175446 under fasting conditions.
Interventions
- DRUG JNJ-54175446 (capsule)
- DRUG JNJ-54175446 (suspension)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-10 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02930694
The ClinicalTrials.gov registry entry for NCT02930694 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JNJ-54175446 (capsule) is the first listed.
NCT02930694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02930694 about?
NCT02930694 is a clinical study titled "A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants". The primary purpose of the study is to investigate the plasma pharmacokinetics and bioavailability (BA) of a single dose of a solid dose formulation with 2 different strengths of JNJ-54175446 (50 milligram \[mg\] and 100 mg capsules) relative to the suspension of JNJ-54175446 under fasting condition...
What is the current status of trial NCT02930694?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-10. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02930694?
The interventions under investigation include: JNJ-54175446 (capsule) (DRUG), JNJ-54175446 (suspension) (DRUG).
Who is sponsoring clinical trial NCT02930694?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.